Long-Term Treatment of a VIPoma With Somatostatin Analogue Resulting in Remission of Symptoms and Possible Shrinkage of Metastases

Kraenzlin, Marius E.; Ch’ng, J. L. C.; Wood, Susan M.; Carr, Denis H.; Bloom, Stephen R.

doi:10.1016/s0016-5085(85)80153-0

Cited by 186 publications

(47 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the previous studies, it was believed that somatostatin inhibited cell growth [7] . However,the recent studiesdemonstrated that somatostatin could stimulate tumor cell growth [8,9] .…”

Section: Discussionmentioning

confidence: 99%

Expression of somatostatin mRNA in various differentiated types of gastric carcinoma

Zhang¹

1998

WJG

View full text Add to dashboard Cite

AIM To investigate the expression of somatostatin mRNA in various differentiated types of gastric carcinoma. METHODS By using in situ hybridization and immunohistochemical techniques, the expression of somatostatin mRNA and somatostatin immunoreactivity in the normal gastric mucosa, the poorly, moderately and well-differentiated gastric carcinomas, and various clinical stages of carcinoma were observed. RESULTS In comparison with the normal gastric mucosa, the significantly increased expression of somatostatin mRNA positive cells was displayed in gastric carcinoma ( t = 2.681, P < 0.01). The positive signal cells were distributed in a scattered form or aggregated as a mass or a cord, and the positive cells were more significantly enhanced in poorly differentiated carcinomas than those in well and moderately differentiated carcinomas (t = 2.962, P< 0.01). The somatostatin mRNA hybridization signals in stages III and IV of gastric carcinoma were significantly higher than those in stages I and II. The results of somatostatin immunoreactivity were consistent with those of in situhybridization. CONCLUSION The alteration of the expression of somatostatin mRNA was associated with the development of gastric carcinoma and may play an important role in the process of tumor differentiation.

show abstract

“…In the previous studies, it was believed that somatostatin inhibited cell growth [7] . However,the recent studiesdemonstrated that somatostatin could stimulate tumor cell growth [8,9] .…”

Section: Discussionmentioning

confidence: 99%

Expression of somatostatin mRNA in various differentiated types of gastric carcinoma

Zhang¹

1998

WJG

View full text Add to dashboard Cite

show abstract

“…A definite improvement in the symptoms was rated as a response. Reductions in the tumour mass were seen in isolated cases of gastrinoma or VIPoma [10,15]. The success rate was particularly high in cases of VIPoma and slightly lower in cases of carcinoids.…”

Section: Treatmentmentioning

confidence: 91%

“…This can mean a considerable improve ment in the quality of life of such patients. One striking effect of octreotide treatment is the reduction of the pro fuse secretory diarrhoea induced by VIPomas [10][11][12], Dehydration and hypokalaemia are reversed and the pa tients gain weight. The mean plasma VIP levels during the treatment decreased by about 60% [13].…”

Section: Treatmentmentioning

confidence: 99%

Gastroenteropancreatic Endocrine Tumours: Effects of Octreotide Treatment

Meier¹

1994

Dig Surg

View full text Add to dashboard Cite

Octreotide is particularly useful in patients with resistant acromegaly and some gastroenteropancreatic (GEP) tumours, e.g. VIPomas, carcinoids and glucagonomas. The efficacy of octreotide can be attributed to its action regarding somatostatin receptors on GEP tumour cells. The symptoms of these tumours are due to a greater extent to the peptides they secrete than to their actual size. In most patients these symptoms improve or disappear completely with octreotide treatment. Side effects of treatment are mainly mild and do not necessitate withdrawal of the treatment. Octreotide is currently the drug of choice for controlling the symptoms of inoperable GEP tumours.

show abstract

“…Biochemical analysis assists in establishing a diagnosis when a marked elevation (>200 pg/dl) in the serum level of VIP is found (Smith et al, 1998). Symptomatic control of the diarrhea can be achieved with somatostatin analogues (Kraenzlin et al, 1985 …”

Section: Vipomamentioning

confidence: 99%